VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that Lota Zoth has been appointed as its Chair of the Board of Directors. Ms. Zoth succeeds Nick Bedford, who has retired from his …
Latest News From Lumira Ventures
Health Quality Ontario Recommends Public Funding of Gliolan®
MONTREAL, Sept. 12, 2019 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) announces that Health Quality Ontario, under the guidance of the Ontario Health Technology Advisory Committee, has recommended public funding of Gliolan® (5-aminolevulinic acid hydrochloride) …
Aurinia Pharmaceuticals Enters into Agreement with Jefferies LLC.
VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has entered into an Open Market Sales Agreement with …
Cardiac Dimensions Carillon® System Improves FMR & Slows Worsening of Heart Failure
Study Conclusions Yesterday, Cardiac Dimensions met its primary endpoint. Results from the REDUCE FMR clinical study were published in the Journal of American College of Cardiology: Heart Failure. In this first blinded and sham-controlled randomized controlled trial of a percutaneous …
Corvia Medical & PhysIQ Partner in Phase 3 Heart Failure Clinical Trial
Corvia Medical is actively enrolling and sponsoring a first-of-its-kind 100+ site, global, Phase 3 clinical trial leveraging continuous multivariate wearable sensor data and artificial intelligence (AI) based analytics to evaluate the clinical efficacy of it’s InterAtrial Shunt Device (IASD®) in …
Exact Imaging Receives CE Mark of Approval
TORONTO, Sept. 10, 2019 /PRNewswire/ – Exact Imaging, the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, has received CE Mark approval for its Sterile Transperineal Needle Guide for use with Exact Imaging EV29L transducer. …
Bardy Diagnostics™ Receives 510(k) Clearance from U.S. FDA for its 14-Day CAM™ patch
SEATTLE, Sept. 6, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the 14-Day version of the Carnation Ambulatory Monitor …
Edesa Biotech Receives Approval from Health Canada for Clinical Study
TORONTO, ON / ACCESSWIRE / September 5, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from Health Canada to begin a clinical study of its investigational drug, EB02, which the company is developing as a potential …
Satsuma Pharmaceuticals Inc. Proposes Initial Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma”), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced that it has commenced an underwritten initial public offering of …
Edesa Biotech Reports Quarterly Financial Results
TORONTO, ON / ACCESSWIRE / August 14, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2019 and provided an update on its business. During the quarter, …
Bardy Diagnostics™ Selected As 1 of 6 Disruptive MedTech Startups for the HealthTech Arkansas Accelerator Program
SEATTLE, Aug. 9, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that HealthTech Arkansas, a healthcare accelerator and investment fund that connects early-stage healthcare companies with disruptive technologies to Arkansas healthcare providers, has …
FDA Grants G1 Therapeutics Breakthrough Therapy Designation in Q2 2019 Corporate and Financial Update
Related Article: G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2019. …
Aurinia Releases Q2 2019 Financial Results
Related Article: Aurinia Reports First Quarter 2019 Financial Results & Recent Operational Highlights Review condensed consolidated financials here: https://ir.auriniapharma.com/press-releases/detail/153 VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused …
Zymeworks Releases Q2 2019 Financial Results
Related Article: Zymeworks Reports 2019 First Quarter Results VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2019. “We had a notable second …
Endotronix Receives conditional IDE approval from the US Food & Drug Administration
Related Article: Endotronix Receives 13485:2016 certification from the British Standards Institution (BSI) for its Quality Management System LISLE, Ill., Aug. 1, 2019 /PRNewswire/ — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced …